| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
The aim of the present study is to evaluate periodontal condition before and after medication with inhibitors of tumor necrosis factor (TNF) and interleukin-6 receptor (IL-6R) in patients with rheumatoid arthritis (RA) and periodontitis who exhibits increased serum levels of TNF and IL-6. The results indicated that patients with RA and periodontitis showed a decreased level of periodontal inflammation and destruction as well as a decrease in serum expressions of TNF, IL-6, and acute-phase proteins following TNF and IL-6R targeted therapies. These results suggest that TNF and IL-6R targeted therapies may lead to a clinical improvement of periodontal condition in patients with RA and periodontitis.
|
